|
|
 Previous Article | Table of Contents | Next Article 
Increased incidence of second neoplasms in patients treated with interferon
alpha 2b for hairy cell leukemia: a clinicopathologic assessment [see
comments]
P Kampmeier, R Spielberger, J Dickstein, R Mick, H Golomb and JW Vardiman
Department of Pathology, University of Chicago Hospitals and Clinics, IL.
We report that there is an unexpectedly high incidence of second neoplasms
in patients after treatment of hairy cell leukemia (HCL) with interferon
alpha 2b (IFN). In a cohort of 69 patients with HCL entered in a protocol
using IFN as the primary treatment, and followed thereafter for a median of
91 months (range, 0.2 to 109 months), 13 patients (19%) developed a second
neoplasm. Six neoplasms were of hematopoietic origin, whereas the remaining
seven were adenocarcinomas. The expected number of second tumors in this
cohort is three (based on calculations from the National Cancer Institute's
SEER data), so the excess frequency (observed:expected) is 4.33. However,
the excess frequency is even greater for the hematopoietic neoplasms; the
expected frequency is 0.15, whereas six hematopoietic tumors occurred, for
an observed:expected ratio of 40. In general, the second neoplasms have
behaved aggressively, and the median survival after diagnosis of the second
neoplasm was only 8.8 months. Although we cannot entirely exclude the
possibility that IFN therapy has some direct oncogenic effect, we suspect
that increased frequency of second tumors is related to prolonged survival
of patients who are immunocompromised because of HCL and thus prone to
develop second tumors. If so, the frequency of second neoplasms in patients
with HCL may be even greater in the future with continued improvements in
therapy.
Volume 83,
Issue 10,
pp. 2931-2938,
05/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Hisada, B. E. Chen, E. S. Jaffe, and L. B. Travis
Second Cancer Incidence and Cause-Specific Mortality Among 3104 Patients With Hairy Cell Leukemia: A Population-Based Study
J Natl Cancer Inst,
February 7, 2007;
99(3):
215 - 222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. McLaughlin, E. Estey, A. Glassman, J. Romaguera, F. Samaniego, A. Ayala, K. Hayes, A. M. Maddox, H. A. Preti, and F. B. Hagemeister
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
Blood,
June 15, 2005;
105(12):
4573 - 4575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. von Rohr, S.-F. H. Schmitz, A. Tichelli, U. Hess, D. Piguet, M. Wernli, N. Frickhofen, G. Konwalinka, G. Zulian, M. Ghielmini, et al.
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
Ann. Onc.,
October 1, 2002;
13(10):
1641 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, P. L. Zinzani, A. Frassoldati, M. Vinceti, A. Mode, L. Annino, T. Chisesi, G. Pagnucco, R. Invernizzi, M. Spriano, et al.
Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up
J. Clin. Oncol.,
February 1, 2002;
20(3):
638 - 646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F A Wandroo, D Bareford, and F El-Jehani
Chronic myeloid leukaemia occurring in a patient with hairy cell leukaemia
J. Clin. Pathol.,
December 1, 2000;
53(12):
940 - 941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. W. Flinn, K. J. Kopecky, M. K. Foucar, D. Head, J. M. Bennett, R. Hutchison, W. Corbett, P. Cassileth, T. Habermann, H. Golomb, et al.
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin
Blood,
November 1, 2000;
96(9):
2981 - 2986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, D. A. Vena, J. Barrett, and B. Freidlin
Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias
J. Clin. Oncol.,
August 1, 1999;
17(8):
2454 - 2454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Saven, C. Burian, J. A. Koziol, and L. D. Piro
Long-Term Follow-Up of Patients With Hairy Cell Leukemia After Cladribine Treatment
Blood,
September 15, 1998;
92(6):
1918 - 1926.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Au, R. J. Klasa, R. Gallagher, N. Le, R. D. Gascoyne, and J. M. Connors
Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience
Blood,
August 15, 1998;
92(4):
1160 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, S. Jagannath, D. H. Vesole, S. Naucke, B. Cheson, S. Mattox, D. Bracy, S. Salmon, J. Jacobson, J. Crowley, et al.
Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma
Blood,
February 1, 1997;
89(3):
789 - 793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
